Post-HSCT graft failure due to refractory human cytomegalovirus successfully treated with haploidentical donor-derived immunoglobulins and stem cell graft infusion : A case report
Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved..
BACKGROUND: Human cytomegalovirus (HCMV) remains an important cause of transplant-related morbidity and mortality. The incidence of HCMV recurrence in the donor seronegative (D-)/recipient seropositive (R+) group is significantly higher than in other serostatus combinations as a result of a lack of pre-existing HCMV-specific memory T-lymphocytes in the donor, coupled with the eradication of the recipient's cellular immunity due to the conditioning regimen.
CASE PRESENTATION: We describe the case of an 8-year-old βE-thalassemic girl from Bangladesh who was seropositive for human cytomegalovirus (HCMV) and underwent hematopoietic stem cell transplantation from a HLA-matched, unrelated, HCMV-seronegative donor. Despite administering antiviral prophylaxis with commercial pooled anti-HCMV immunoglobulin (Ig) from day +1, the post-transplant course was complicated by prompt viral reactivation, and foscarnet therapy was initiated. The virus was refractory to treatment, leading rapidly to complete bone marrow failure, and targeted immunotherapy was proposed as a second-line therapy. Hypothesizing that the patient and her relatives may have been exposed to similar HCMV strains, we selected the patient's mother, who presented a high HCMV antibody titer, as the donor of virus strain-specific anti-HCMV Ig and T-lymphocytes. Complete viral clearance was achieved after two transfusions of the mother's plasma. Subsequently, the patient underwent a haploidentical rescue transplant, promptly reaching full hematological recovery.
CONCLUSION: These findings suggest that treatment with virus strain-specific Ig may offer a new therapeutic option for critically ill patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:188 |
|---|---|
| Enthalten in: |
Antiviral research - 188(2021) vom: 09. Apr., Seite 105024 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Baldo, Francesco [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
364P9RVW4X |
|---|
| Anmerkungen: |
Date Completed 12.10.2021 Date Revised 16.07.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.antiviral.2021.105024 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM321376587 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM321376587 | ||
| 003 | DE-627 | ||
| 005 | 20231225175657.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.antiviral.2021.105024 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1071.xml |
| 035 | |a (DE-627)NLM321376587 | ||
| 035 | |a (NLM)33577809 | ||
| 035 | |a (PII)S0166-3542(21)00014-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Baldo, Francesco |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Post-HSCT graft failure due to refractory human cytomegalovirus successfully treated with haploidentical donor-derived immunoglobulins and stem cell graft infusion |b A case report |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.10.2021 | ||
| 500 | |a Date Revised 16.07.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a BACKGROUND: Human cytomegalovirus (HCMV) remains an important cause of transplant-related morbidity and mortality. The incidence of HCMV recurrence in the donor seronegative (D-)/recipient seropositive (R+) group is significantly higher than in other serostatus combinations as a result of a lack of pre-existing HCMV-specific memory T-lymphocytes in the donor, coupled with the eradication of the recipient's cellular immunity due to the conditioning regimen | ||
| 520 | |a CASE PRESENTATION: We describe the case of an 8-year-old βE-thalassemic girl from Bangladesh who was seropositive for human cytomegalovirus (HCMV) and underwent hematopoietic stem cell transplantation from a HLA-matched, unrelated, HCMV-seronegative donor. Despite administering antiviral prophylaxis with commercial pooled anti-HCMV immunoglobulin (Ig) from day +1, the post-transplant course was complicated by prompt viral reactivation, and foscarnet therapy was initiated. The virus was refractory to treatment, leading rapidly to complete bone marrow failure, and targeted immunotherapy was proposed as a second-line therapy. Hypothesizing that the patient and her relatives may have been exposed to similar HCMV strains, we selected the patient's mother, who presented a high HCMV antibody titer, as the donor of virus strain-specific anti-HCMV Ig and T-lymphocytes. Complete viral clearance was achieved after two transfusions of the mother's plasma. Subsequently, the patient underwent a haploidentical rescue transplant, promptly reaching full hematological recovery | ||
| 520 | |a CONCLUSION: These findings suggest that treatment with virus strain-specific Ig may offer a new therapeutic option for critically ill patients | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Human cytomegalovirus | |
| 650 | 4 | |a Hyperimmune plasma infusion | |
| 650 | 4 | |a Post-transplant graft failure | |
| 650 | 4 | |a Targeted immunotherapy | |
| 650 | 7 | |a Immunoglobulins |2 NLM | |
| 650 | 7 | |a Foscarnet |2 NLM | |
| 650 | 7 | |a 364P9RVW4X |2 NLM | |
| 700 | 1 | |a Suárez, Nicolás M |e verfasserin |4 aut | |
| 700 | 1 | |a Davison, Andrew J |e verfasserin |4 aut | |
| 700 | 1 | |a Zanon, Davide |e verfasserin |4 aut | |
| 700 | 1 | |a Barbi, Egidio |e verfasserin |4 aut | |
| 700 | 1 | |a Maximova, Natalia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Antiviral research |d 1983 |g 188(2021) vom: 09. Apr., Seite 105024 |w (DE-627)NLM012601756 |x 1872-9096 |7 nnns |
| 773 | 1 | 8 | |g volume:188 |g year:2021 |g day:09 |g month:04 |g pages:105024 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.antiviral.2021.105024 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 188 |j 2021 |b 09 |c 04 |h 105024 | ||